Our global life sciences company brings diagnostic testing & drug development together.
Labcorp’s Beta-Amyloid 42/40 Ratio test quantifies the amount of beta-amyloid 42 and 40 proteins in a CSF patient sample and computes the ratio of those proteins, providing an indication of AD pathology:
|Test Name||Beta Amyloid 42/40 Ratio, CSF|
|Volume (min-max)||5mL – 8mL|
|Collection tube||Sarstedt® 62.610.018 10mL tube only|
|Refrigeration||Required; refrigerate immediately after collection|
This assay is currently not available in New York state.
*Beta-amyloid testing performed by Labcorp under this program is provided through the financial support of Biogen. The cost of the testing must not be billed to any patient or other third-party payor, including any commercial health plan or government health care program. Health care providers are responsible for ordering testing in accordance with their professional medical judgment and applicable laws. Neither health care providers nor patients who participate in this program have any obligation to recommend, purchase, order, prescribe, promote, or use any products or services from Biogen or Labcorp. The program is subject to termination or modification at any time. Limitations may apply.
† There is no cost for the beta-amyloid test itself. However, the lumbar puncture procedure required to obtain the sample for the testing is not included under this program. Thus, patients may have out-of-pocket costs related to the lumbar puncture procedure, or other related costs, depending on how it is billed by their healthcare provider and covered by their third-party payer.